Evaluation of AKI by Measuring the NephroCheck Test After Pediatric Cardiac Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-30

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood and urine samples of over 200 pediatric subjects (over 28 days to 3 years) undergoing complex cardiac surgery with cardiopulmonary bypass (CPB) will be collected at several time points to measure corresponding biomarkers such as serum creatinine, serum urea concentration, or NephroCheck test (\[TIMP-2\]\*\[IGFBP7) to evaluate the diagnostic performance of AKI by NephroCheck test .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Urine Biomarkers to Predict Acute Kidney Injury After Pediatric Cardiac Surgery

NCT05637424

Acute Kidney Injury Congenital Cardiac Disorders

COMPLETED

Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury

NCT01531985

Congenital Heart Disease

COMPLETED

A Predictive Score System for AKI Following Pediatric Cardiac Surgery

NCT05489263

Congenital Heart Disease Surgery--Complications Acute Kidney Injury

UNKNOWN

Predicting Poor Outcomes of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers

NCT04962412

Acute Kidney Injury Critical Illness

COMPLETED

Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients

NCT02499185

Acute Kidney Injury Arterial Hypertension Obesity +4 more

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At least 200 subjects having undergone pediatric cardiac surgery with cardiopulmonary bypass (CPB). Enrollment will continue with a maximum of 350 subjects until 30 cases of AKI (stage 2 and 3) are reached.

Blood and urines samples will be collected at several time points to measure biomarkers and set up a biobank.

The samples used within the scope of this protocol will be fresh urine samples (1 to 2 ml) and blood samples.

Urine samples for \[TIMP-2\]\*\[IGFBP7\] measurements will be taken from each subject included in the study during the first 48 hours following cardiopulmonary bypass initiation according to the following schedule:

* baseline before initiation of cardiopulmonary bypass (CPB, 0h).
* \- 2h, 4h, 6h, 8h, 12h, 24h, 48h after initiation of CPB

Blood samples for serum creatinine and urea concentration measurement will be taken from each subject included in the study during the first 48 hours following cardiopulmonary bypass initiation according to the following schedule:

* baseline before initiation of cardiopulmonary bypass (CPB, 0h).
* 12h, 24h, 48h, 60h after initiation of CPB

Primary objective:

To evaluate the proportion of subjects predicted to be at risk of AKI (stage 2 and 3) using at least one measurement of NephroCheck in subjects having undergone pediatric cardiac surgery.

Secondary objectives:

* To evaluate the incidence of AKI (stage 2 and 3) according to the KDIGO guideline
* To study the kinetic profile of cell cycle arrest biomarkers (TIMP-2\*IGFBP-7) during the first 48 hours in subjects having undergone pediatric cardiac surgery
* To determine the baseline values of \[TIMP-2\]\*\[IGFBP7\] in the targeted population before surgery
* To determine profile differences of \[TIMP-2\]\*\[IGFBP7\] between AKI (stage 2 and 3) and non-AKI groups
* To evaluate the diagnostic performances of \[TIMP-2\]\*\[IGFBP7\] to predict AKI after pediatric cardiac surgery using a cut-off value of 0.3

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Cardiac Disease Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cardiac surgery

pediatric cardiac surgery with cardiopulmonary bypass

Intervention Type PROCEDURE

NephroCheck test

Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must sign the consent form
* Clinical diagnosis of complex congenital heart surgery (Risk Adjusted classification for Congenital Heart Surgery \[RACHS\] score \>=2)
* Must undergo elective cardiac surgery with CPB

Exclusion Criteria

* Clinical diagnosis of severe pre-existing renal insufficiency (SCr \>2 times age-adjusted normal range)
* Significant abnormalities of the kidneys or genitourinary tract

Minimum Eligible Age

28 Days

Maximum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No